Invention Grant
- Patent Title: Solubility optimization of immunobinders
-
Application No.: US15378649Application Date: 2016-12-14
-
Publication No.: US10221237B2Publication Date: 2019-03-05
- Inventor: Leonardo Borras , David Urech
- Applicant: ESBATech, an Alcon Biomedical Research Unit LLC
- Applicant Address: CH Schlieren
- Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
- Current Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
- Current Assignee Address: CH Schlieren
- Agent Jason J. Derry
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/24 ; C07K16/22

Abstract:
The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.
Public/Granted literature
- US20170096482A1 SOLUBILITY OPTIMIZATION OF IMMUNOBINDERS Public/Granted day:2017-04-06
Information query